# Positive Surgical Margins Rate and EGFR Family Members Expression in Prostate Cancer Treated With Bicalutamide

> **NCT00421694** · PHASE2,PHASE3 · COMPLETED · sponsor: **University of L'Aquila** · enrollment: 119 (—)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Bicalutamide

## Key facts

- **NCT ID:** NCT00421694
- **Lead sponsor:** University of L'Aquila
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 119 (—)
- **Last updated:** 2007-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00421694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00421694, "Positive Surgical Margins Rate and EGFR Family Members Expression in Prostate Cancer Treated With Bicalutamide". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00421694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*